AQ280 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 98 | Eosinophilic gastrointestinal disease | 1 |
98. Eosinophilic gastrointestinal disease
Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05485779 (ClinicalTrials.gov) | July 20, 2022 | 15/7/2022 | SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects | A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, and Food Effect Evaluation Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of AQ280 in Healthy Subjects | Eosinophilic Esophagitis (EoE) | Drug: AQ280;Drug: Placebo | AQILION AB | NULL | Recruiting | 18 Years | 65 Years | All | 64 | Phase 1 | United Kingdom |